Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 70518-1781

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1781). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 250mg 70518 1781 01

Divalproex Sodium is an extended-release medication in the form of a 250mg tablet. This package contains 100 tablets with the label "HD2". The medication is available only by prescription and must be kept out of reach of children. The package insert should be consulted for usage instructions. The medication should be stored between 20-26°C (63-77°F) with excursions up to 15-30°C (59-86°F) allowed. The lot number, expiration date, and source NDC are all present on the packaging. The product was manufactured by Aurcbindo Pharma in Dayton, NJ and repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Divalproex Sodium 250mg 70518 1781 02

Divalproex Sodium is a medication that comes in the form of an extended-release 250mg tablet. This drug is only available with a prescription and has an NDC # of 70518-1781-02. The manufacturer is Aurcbindo Pharma in Dayton, NJ. The medication should be kept out of reach of children and should be stored at temperatures between 20-26°C, with excursions permitted to 15-30°C. The directions for use can be found in the package insert. This medication has been repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Divalproex Sodium Extended-Release 250 mg tablets. It comes in a package of 30 tablets and is used by prescription only. It includes information about the NDC number, the manufacturer, and the lot number. The packaging also suggests keeping the medication away from children and provides storage instructions. The user should refer to the package insert for directions on how to use the medication. The tablets have been repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Figure 1 (Divalproex Fig1)

The text describes a graph titled "Reduction in CPS Rate" which compares the effectiveness of Divalproex Sodium Delayed-Release Tablets to a placebo in improving patient condition. The graph shows a 50% improvement in patients treated with Divalproex Sodium Tablets compared to those who received a placebo. The graph also includes three categories: "Improvement", "No Change", and "Worsening".*

FDA Label Image

Figure 2 (Divalproex Fig2)

The text describes figure 2, which shows the percentage reduction in CPS (Central Nervous System) rate for patients taking high dose and low dose Divalproex Sodium Delayed-Release Tablets. The figure also compares the improvement, no change, and worsening of patients' symptoms after taking the medication.*

FDA Label Image

Figure-3 (Divalproex Fig3)

This appears to be a mixture of numerical, chemical and pharmaceutical information. It is not clear what the context or purpose of these lines are. Without more information, it is not possible to provide a more useful description.*

FDA Label Image

Structure (Divalproex Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.